Rein Therapeutics, Inc.

Analysis for Ticker: RNTX

Rein Therapeutics Inc is a company that claims to develop medicine for rare lung diseases like fibrosis, but its real business is a mathematical machine designed to feed lenders while original shareholders are left with nothing. The company is in a terminal crisis, begging the public to buy 30 million new shares for about 1,66$ each just to pay back predatory loans that are coming due in 06/2026. The math for a child is simple: you are asked to pay 1,66$ for a piece of paper that is actually worth less than zero because the company has a negative 0,11$ book value. Even after giving them money, the value of that share instantly drops to just 0,65$, which means a loss of 1,01$ the very second it is bought. With an accumulated deficit of over 401,0$ million and auditors who officially doubt the company can even stay open, the business is a burning building where the exits are blocked by debt. The path to this collapse began in 01/2025 when the company changed its name from Aileron Therapeutics. They were focused on drugs named LTI-03, LTI-01, and LTI-05, while also trying to sell an old drug called ALRN-6924 to Advancium Health Network. In 04/2025, they signed a 17,0$ million contract for a clinical trial, but they also started giving away the company's value to insiders. They let Bios Partners and others change their special stock coupons, called warrants, so they could buy shares for 1,60$ instead of 4,89$, or even for less than 0,01$. By 07/2025, the government stopped their drug tests because they could not prove the medicine was safe for rats, which meant they were spending money without making any progress.